V. Institut-de and . Sanitaire, Infection par le VIH et les IST bactériennes, Disponible sur, 2017.

P. Morlat, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Prise en charge médicale des personnes vivant avec le VIHRecommandations du groupe d'experts, 2017.

F. Raffi, P. Girard, Y. Calvez, L. Hocqueloux, and . Bithérapies, Nouvelles options de traitement antirétroviral. Symposium ViiV. Journée Nationales d'Infectiologie, vol.13, 2018.

, Nantes

, Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies, Lancet HIV, vol.4, issue.8, pp.349-56, 2017.

P. Morlat, Prise en charge médicale des personnes vivant avec le VIHRecommandations du groupe d'experts. Actualisations 2018 des recommandations du groupe d'expert -Initiation d'un premier traitement antirétroviral, Avr, 2018.

, Disponible sur, 2017.

P. Morlat, Prise en charge médicale des personnes vivant avec le VIHRecommandations du groupe d'experts. Actualisations 2017 des recommandations du groupe d'experts -Optimisation d'un traitement antirétroviral en situation de succès virologique, Juil, 2017.

M. A. Valantin, S. Lambert-niclot, P. Flandre, L. Morand-joubert, A. Cabiè et al., Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study, J Antimicrob Chemother, vol.67, issue.3, pp.691-696, 2012.

N. Clumeck, A. Rieger, D. Banhegyi, W. Schmidt, A. Hill et al., 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline, J Antimicrob Chemother, vol.66, issue.8, pp.1878-85, 2011.

N. I. Paton, W. Stöhr, A. Arenas-pinto, M. Fisher, I. Williams et al., Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial, Lancet HIV, vol.2, issue.10, pp.417-426, 2015.

A. Mondi, M. Fabbiani, N. Ciccarelli, M. Colafigli, D. &apos;avino et al., Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIVinfected patients with virological suppression: 144 week follow-up of the AtLaS pilot study, J Antimicrob Chemother, vol.70, issue.6, pp.1843-1852, 2015.

D. Giambenedetto, S. Fabbiani, M. , Q. Roldan, E. Latini et al., Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M), J Antimicrob Chemother, vol.72, issue.4, pp.1163-71, 2017.

J. A. Perez-molina, R. Rubio, A. Rivero, J. Pasquau, I. Suárez-lozano et al., Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial, Lancet Infect Dis, vol.15, issue.7, pp.775-84, 2015.

J. R. Arribas, P. Girard, R. Landman, J. Pich, J. Mallolas et al., Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavirritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-96 inferiority trial, Lancet Infect Dis, vol.15, issue.7, pp.785-92, 2015.

F. Pulido, E. Ribera, M. Lagarde, I. Pérez-valero, R. Palacios et al., Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial, Clin Infect Dis, vol.65, issue.12, pp.2112-2120, 2017.

F. Maggiolo, D. Filippo, E. Valenti, D. , S. Ortega et al., NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe), J Acquir Immune Defic Syndr, vol.72, issue.1, pp.46-51, 2016.

F. Raffi, A. G. Babiker, L. Richert, J. Molina, E. C. George et al., Ritonavirboosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised noninferiority trial, Lancet, vol.384, issue.9958, pp.1942-51, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01108186

B. Taiwo, L. Zheng, S. Gallien, R. M. Matining, D. R. Kuritzkes et al., Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262), AIDS, vol.25, issue.17, pp.2113-2135, 2011.

T. Nishijima, H. Gatanaga, T. Shimbo, H. Komatsu, T. Endo et al., Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study, PLoS ONE, vol.8, issue.8, pp.2091-2100, 2013.

I. Ofotokun, A. N. Sheth, S. E. Sanford, K. A. Easley, N. Shenvi et al., A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study, AIDS Res Hum Retroviruses, vol.28, issue.10, pp.1196-206, 2012.

L. Calza, I. Danese, E. Magistrelli, V. Colangeli, R. Manfredi et al., Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors, HIV Clin Trials, vol.17, issue.1, pp.38-47, 2016.

A. F. Capetti, M. V. Cossu, G. Orofino, G. Sterrantino, G. Cenderello et al.,

, A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data, BMC Infect Dis, vol.17, issue.1, p.658, 2017.

J. Chinen and W. T. Shearer, Molecular virology and immunology of HIV infection, J Allergy Clin Immunol, vol.110, issue.2, pp.189-98, 2002.

D. J. Hu, A. Buvé, J. Baggs, G. Van-der-groen, and T. J. Dondero,

, subtype play in transmission and pathogenesis? An epidemiological perspective, AIDS, vol.13, issue.8, pp.873-81, 1999.

E. Pilly, O. Épaulard, L. Berre, and R. Item, Infection à VIH ECN-Pilly, vol.165, 2017.

S. Sierra, B. Kupfer, and R. Kaiser, Basics of the virology of HIV-1 and its replication, J Clin Virol, vol.34, issue.4, pp.233-277, 2005.

D. R. Littman, Chemokine receptors: keys to AIDS pathogenesis?, Cell, vol.93, issue.5, pp.677-80, 1998.

C. Tantillo, J. Ding, A. Jacobo-molina, R. G. Nanni, P. L. Boyer et al., Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance, J Mol Biol, vol.243, issue.3, pp.369-87, 1994.

R. H. Miller and N. Sarver, HIV accessory proteins: emerging therapeutic targets, Mol Med, vol.1, issue.5, pp.479-85, 1995.

M. S. Cohen, G. M. Shaw, A. J. Mcmichael, and B. F. Haynes, Acute HIV-1 Infection, N Engl J Med, vol.364, issue.20, pp.1943-54, 2011.

J. P. Moore, A. Trkola, and T. Dragic, Co-receptors for HIV-1 entry, Curr Opin Immunol

B. M. Branson, State of the art for diagnosis of HIV infection, Clin Infect Dis, vol.45, pp.221-225, 2007.

, ONUSIDA. Fiche d'information -Dernières statistiques sur l'état de l'épidémie de sida

. Onusida, , 2018.

F. Lot, F. Cazein, J. Pillonel, and N. Ndeikoundam, Co-infections par les IST lors de la découverte de la séropositivité VIH, Bull Epidémiol Hebd, pp.596-600, 2017.

P. Cahn, R. Kaplan, P. E. Sax, K. Squires, J. Molina et al., Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial, Lancet HIV, vol.4, issue.11, pp.486-94, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01745628

R. Krishna, M. L. Rizk, P. Larson, V. Schulz, F. Kesisoglou et al., Single-and MultipleDose Pharmacokinetics of Once-Daily Formulations of Raltegravir, Clin Pharmacol Drug Dev, vol.7, issue.2, pp.196-206, 2018.

N. Mulligan, B. M. Best, E. Capparelli, A. Stek, E. Barr et al., Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women. Conference on Retroviruses and Opportunistic Infections, 2016.

M. Boston, , p.438

P. Morlat, Prise en charge médicale des personnes vivant avec le VIHRecommandations du groupe d'experts. Actualisations 2017 des recommandations du groupe d'expert -Co-infections par les virus des hépatites, 2017.

R. Ortiz, E. Dejesus, H. Khanlou, E. Voronin, J. Van-lunzen et al., Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatmentnaive HIV-1-infected patients at week 48, AIDS, vol.22, issue.12, pp.1389-97, 2008.

E. Lathouwers, D. Meyer, S. Dierynck, I. Van-de-casteele, T. Lavreys et al., Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis, Antivir Ther (Lond), vol.16, issue.1, pp.99-108, 2011.

C. Orkin, E. Dejesus, H. Khanlou, A. Stoehr, K. Supparatpinyo et al., Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial, HIV Med, vol.14, issue.1, pp.49-59, 2013.

B. Clotet, N. Bellos, J. Molina, D. Cooper, J. Goffard et al., Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials, Lancet, vol.369, issue.9568, pp.1169-78, 2007.

J. V. Madruga, D. Berger, M. Mcmurchie, F. Suter, D. Banhegyi et al.,

, Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial, Lancet, vol.370, issue.9581, pp.49-58, 2007.

L. Ryom, J. D. Lundgren, W. El-sadr, P. Reiss, O. Kirk et al., Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study, Lancet HIV, vol.5, issue.6, pp.291-300, 2018.

J. Molina, J. Andrade-villanueva, J. Echevarria, P. Chetchotisakd, J. Corral et al., Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study, Lancet, vol.372, issue.9639, pp.646-55, 2008.

E. S. Daar, C. Tierney, M. A. Fischl, P. E. Sax, K. Mollan et al., Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1, Ann Intern Med, vol.154, issue.7, pp.445-56, 2011.

N. Clumeck, J. Molina, K. Henry, J. Gathe, J. K. Rockstroh et al., A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results, J Acquir Immune Defic Syndr, vol.65, issue.3, pp.121-124, 2014.

J. L. Lennox, R. J. Landovitz, H. J. Ribaudo, I. Ofotokun, L. H. Na et al., A phase III comparative study of the efficacy and tolerability of three non-nucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve HIV-1-infected volunteers : a randomized, controled trial, Ann Intern Med, vol.161, issue.7, pp.461-71, 2014.

J. L. Lennox, E. Dejesus, A. Lazzarin, R. B. Pollard, J. Madruga et al., Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, Lancet, vol.374, issue.9692, pp.796-806, 2009.

J. K. Rockstroh, E. Dejesus, J. L. Lennox, Y. Yazdanpanah, M. S. Saag et al., Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK, J Acquir Immune Defic Syndr, vol.63, issue.1, pp.77-85, 2013.

M. Markowitz, B. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan et al., Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study, J Acquir Immune Defic Syndr, vol.46, issue.2, pp.125-158, 2007.

B. Akil, G. Blick, D. P. Hagins, M. N. Ramgopal, G. J. Richmond et al.,

, Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study, Antivir Ther (Lond), vol.20, issue.3, pp.343-351, 2015.

P. E. Sax, E. Dejesus, A. Mills, A. Zolopa, C. Cohen et al., Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, doubleblind, phase 3 trial, analysis of results after 48 weeks, Lancet, vol.379, issue.9835, pp.2439-2487, 2012.

D. A. Wohl, C. Cohen, J. E. Gallant, A. Mills, P. E. Sax et al.,

, efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results, J Acquir Immune Defic Syndr, vol.65, issue.3, pp.118-120, 2014.

J. Molina, A. Lamarca, J. Andrade-villanueva, B. Clotet, N. Clumeck et al., Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatmentexperienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study, Lancet Infect Dis, vol.12, issue.1, pp.27-35, 2012.

F. Raffi, H. Jaeger, E. Quiros-roldan, H. Albrecht, E. Belonosova et al.,

, Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, noninferiority trial, Lancet Infect Dis, vol.13, issue.11, pp.927-962, 2013.

S. L. Walmsley, A. Antela, N. Clumeck, D. Duiculescu, E. A. Gutiérrez et al.,

, Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection, N Engl J Med, vol.369, pp.1807-1825, 2013.

B. Clotet, J. Feinberg, J. Van-lunzen, K. Antinori, A. Dumitru et al.,

, Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, Lancet, vol.383, issue.9936, pp.2222-2253, 2014.

J. Molina, B. Clotet, J. Van-lunzen, A. Lazzarin, M. Cavassini et al., Oncedaily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO, J Int AIDS Soc, vol.17, issue.4, p.19490, 2014.

P. Cahn, A. L. Pozniak, H. Mingrone, A. Shuldyakov, C. Brites et al., Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study, Lancet, vol.382, issue.9893, pp.700-708, 2013.

F. Raffi, A. Rachlis, C. Brinson, K. Arasteh, M. Górgolas et al., Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials, AIDS, vol.29, issue.2, pp.167-74, 2015.

J. Jiang, X. Xu, W. Guo, J. Su, J. Huang et al., Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL-or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials, AIDS Res Ther, vol.13, issue.1, p.30, 2016.

A. Castagna, F. Maggiolo, G. Penco, D. Wright, A. Mills et al.,

, Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravirresistant HIV-1: 24-week results of the phase III VIKING-3 study, J Infect Dis, vol.210, issue.3, pp.354-62, 2014.

C. E. Kandel, S. L. Walmsley, G. Berk, J. Oryszczyn, W. Blok et al., Dolutegravir -a review of the pharmacology, efficacy, and safety in the treatment of HIV, Drug Des Devel Ther, vol.9, pp.3547-55, 2015.

, Unexpectedly High Rate of Intolerance for Dolutegravir in Real-Life Setting. Conference on Retroviruses and Opportunistic Infections, 2016.

M. Boston, Abstract No: 948, vol.102

N. I. Paton, W. Stöhr, L. Oddershede, A. Arenas-pinto, S. Walker et al., The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection, Health Technol Assess, vol.20, issue.21, pp.1-158, 2016.

A. Curran, P. Monteiro, P. Domingo, J. Villar, A. Imaz et al., Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group, J Antimicrob Chemother, vol.69, issue.5, pp.1390-1396, 2014.

T. Bunupuradah, P. Chetchotisakd, J. Ananworanich, W. Munsakul, and S. Jirajariyavej,

P. Kantipong, A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study, Antivir Ther (Lond), vol.17, issue.7, pp.1351-61, 2012.

A. Castagna, V. Spagnuolo, L. Galli, C. Vinci, S. Nozza et al., Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results, AIDS, vol.28, issue.15, pp.2269-79, 2014.

I. Wijting, C. Rokx, C. Boucher, J. Van-kampen, S. Pas et al.,

, Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised noninferiority trial, Lancet HIV, vol.4, issue.12, pp.547-54, 2017.

J. L. Blanco, J. Rojas, R. Paredes, E. Negredo, J. Mallolas et al.,

, Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial, J Antimicrob Chemother, vol.73, pp.1965-71, 2018.

C. Gubavu, T. Prazuck, M. Niang, J. Buret, C. Mille et al., Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients, J Antimicrob Chemother, vol.71, issue.4, pp.1046-50, 2016.

B. Taiwo, R. M. Matining, L. Zheng, M. M. Lederman, C. R. Rinaldo et al., Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy, J Antimicrob Chemother, vol.68, issue.8, pp.1857-61, 2013.

R. J. Bedimo, H. Drechsler, M. Jain, J. Cutrell, S. Zhang et al., The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health, PLoS ONE, vol.9, issue.8, 2014.

G. Madeddu, S. Rusconi, A. Cozzi-lepri, D. Giambenedetto, S. Bonora et al., Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ?50 cp/mL, Infection, vol.45, issue.4, pp.521-529, 2017.

G. Sterrantino, M. Zaccarelli, D. Biagio, A. Biondi, M. L. Antinori et al.,

, Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database, Infection, vol.43, issue.3, pp.339-382, 2015.

D. Carey, S. L. Pett, M. Bloch, H. Wand, K. Macrae et al., A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults, J Acquir Immune Defic Syndr, vol.60, issue.2, pp.143-152, 2012.

M. J. Kozal, S. Lupo, E. Dejesus, J. Molina, C. Mcdonald et al., A nucleosideand ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results, HIV Clin Trials, vol.13, issue.3, pp.119-149, 2012.

M. Le, J. Pain, A. Desnoyer, D. Descamps, C. Katlama et al., Dolutegravir drug intereaction with DRV/r or ATV/r : impact on its pharmacokinecitc ? In: Reviews in Antiviral Therapy & Infectious Diseases

D. C. Washington, Reviews in Antiviral Therapy & Infectious Diseases, pp.77-85, 2015.

M. L. Cottrell, T. Hadzic, and A. Kashuba, Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir, Clin Pharmacokinet, vol.52, issue.11, pp.981-94, 2013.

D. Cattaneo, D. Minisci, A. Riva, V. Cozzi, P. Meraviglia et al., Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?, Antivir Ther, vol.22, issue.4, pp.353-356, 2017.

A. Fantauzzi, O. Turriziani, and I. Mezzaroma, Potential benefit of dolutegravir once daily: efficacy and safety, HIV AIDS (Auckl), vol.5, pp.29-40, 2013.

I. Song, S. S. Min, J. Borland, Y. Lou, S. Chen et al., The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants, J Antimicrob Chemother, vol.51, issue.2, pp.2679-81, 2011.

E. Elliot, M. Cerrone, L. Else, A. A. Bisdomini, E. Khoo et al., Pharmacokinetics of Dolutegravir with and without Darunavir/cobicistat in healthy volunteers, Conference on Retroviruses and Opportunistic Infections, 2007.

U. Boston, , p.468

C. Gervasoni, A. Riva, V. Cozzi, A. Capetti, G. Rizzardini et al., Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference, J Antimicrob Chemother, vol.72, issue.6, pp.1842-1846, 2017.

J. M. Llibre, C. Hung, C. Brinson, F. Castelli, P. Girard et al., Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies, Lancet, vol.391, pp.839-888, 2018.

A. F. Capetti, G. Sterrantino, M. V. Cossu, G. Orofino, G. Barbarini et al., Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort, PLoS ONE, vol.11, issue.10, p.164753, 2016.

C. Katlama, L. Assoumou, M. Valantin, C. Soulié, C. Duvivier et al.,

, Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study, J Antimicrob Chemother, vol.69, issue.6, pp.1648-52, 2014.

A. Gecsa-cohorte and . Aquitaine, Bordeaux: Groupe d'Epidémiologie Clinique du SIDA en Aquitaine, p.Présentation

P. Morlat and . Cohorte-aquitaine--anrs-co3,

, Journée Nationale d'Infectiologie, 2006.

. Bordeaux and . Disponible,

N. I. Paton, C. Kityo, A. Hoppe, A. Reid, A. Kambugu et al., Assessment of second-line antiretroviral regimens for HIV therapy in Africa, N Engl J Med, vol.371, issue.3, pp.234-281, 2014.

V. Joly, C. Burdet, R. Landman, F. Raffi, C. Katlama et al., Promising results of dolutegravir + lamivudine laintenance in anrs 167 Lamidol Trial. Conference on Retroviruses and Opportunistic Infections, pp.13-16, 2017.

W. Seattle, , p.458

L. M. Hofstra, M. Nijhuis, T. Mudrikova, A. Fun, P. Schipper et al., Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses, J Int AIDS Soc, vol.17, issue.4, p.19755, 2014.

C. B. Hurt, J. Sebastian, C. B. Hicks, and J. J. Eron, Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, Clin Infect Dis, vol.58, issue.3, pp.423-454, 2009.

D. E. Dow and J. A. Bartlett, Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV, Infect Dis Ther, vol.3, issue.2, pp.83-102, 2014.

K. Anstett, B. Brenner, T. Mesplede, and M. A. Wainberg, HIV drug resistance against strand transfer integrase inhibitors, Retrovirology, vol.14, issue.1, p.36, 2017.

. Scientific-coordination-committee, S. Marcotullio, M. Andreoni, A. Antinori, A. Monforte et al., The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection, New Microbiol, vol.35, issue.3, pp.259-77, 2012.

D. Costagliola, V. Potard, S. Lang, D. Castro, N. Cotte et al., Is the risk of myocardial infarction in PLHIV associated with atazanavir or darunavir exposure ? 22 nd International AIDS Conference, 2018.

T. Amsterdam and . Netherlands, Abstract No: TUPEB087

C. Cazanave, HIV patients today and 10 years ago -do they have the same needsResults from ANRS CO3 Aquitaine cohort, HIV Glasgow, 2016.

U. K. Glasgow,

Y. Yazdanpanah, C. Fagard, D. Descamps, A. M. Taburet, C. Colin et al., High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial, Clin Infect Dis, vol.49, issue.9, pp.1441-1450, 2009.

C. Fagard, C. Colin, C. Charpentier, A. Rami, C. Jacomet et al., Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial, J Acquir Immune Defic Syndr, vol.59, issue.5, pp.489-93, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00875207

C. Charpentier, B. Roquebert, C. Colin, A. Taburet, C. Fagard et al., Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen, AIDS, vol.24, issue.17, pp.2651-2657, 2010.

C. Charpentier, G. Q. Lee, C. Rodriguez, B. Visseaux, A. Storto et al., Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response, J Antimicrob Chemother, vol.70, issue.7, pp.2090-2096, 2015.

P. E. Sax, A. Pozniak, M. L. Montes, E. Koenig, E. Dejesus et al., Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial, Lancet, vol.390, pp.2073-82, 2017.

M. Tsiang, G. S. Jones, J. Goldsmith, A. Mulato, D. Hansen et al., Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile, Antimicrob Agents Chemother, vol.60, issue.12, pp.7086-97, 2016.

D. A. Margolis, C. C. Brinson, G. Smith, J. De-vente, D. P. Hagins et al., Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial, Lancet Infect Dis, vol.15, issue.10, pp.1145-55, 2015.

D. A. Margolis, J. Gonzalez-garcia, H. Stellbrink, J. J. Eron, and Y. Yazdanpanah,

D. Podzamczer, Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, noninferiority trial, Lancet, vol.390, pp.1499-510, 2017.